Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous adipose-derived mesenchymal stromal cells for knee osteoarthritis
NL-OMON47160Phase 2Active, not recruiting
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Feb 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of autologous adipose-derived mesenchymal stromal cells in knee osteoarthritis (OA), sponsored by Centre Hospitalier Universitaire de Montpellier. Primary endpoints: Change from baseline to month 6 in WOMAC pain score and Change from baseline to month 6 in WOMAC physical function score. Started Feb 2017; status: active, not recruiting.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NL-OMON47160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47160.